Literature DB >> 16946679

Vitreoretinal complications of retinoblastoma treatment.

Khaled A Tawansy1, Michael A Samuel, Maya Shammas, A Linn Murphree.   

Abstract

PURPOSE: To describe complications of the retina and vitreous occurring in children undergoing treatment for retinoblastoma and their clinical management.
METHODS: Retrospective analysis of Ret-Cam images of 206 patients with retinoblastoma treated at one center between 1996 and 2003. Images were studied for vitreoretinal features other than tumor persistence or recurrence. Specifically, complications such as vitreous, retinal, or choroidal hemorrhage, retinal detachment, retinal fold, vascular obstruction, and preretinal or subretinal proliferation were sought.
RESULTS: Vitreoretinal complications of retinoblastoma therapy were identified in 14 patients (6.8%) All had heritable bilateral retinoblastoma. Group 5 Reese-Ellsworth disease was present in 50% (n = 7). All patients had systemic chemotherapy, 50% had external beam radiotherapy, and 64% had more than one local treatment method. Of the 14 patients with a complication, 4 eyes were enucleated for massive recurrence of tumor, 5 eyes were observed, and 5 eyes were treated successfully with vitreoretinal surgery for tractional or rhegmatogenous retinal detachment.
CONCLUSION: Vitreoretinal complications occurred in 6.8% of patients undergoing therapy for retinoblastoma. These included retinal tears, rhegmatogenous and tractional retinal detachment, subretinal fibrosis, vitreous traction bands, preretinal fibrosis, and pseudo-vitreous seeding. They were more often seen when systemic chemotherapy was combined with external beam radiation, cryotherapy, and local chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946679     DOI: 10.1097/01.iae.0000225350.83931.f6

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  9 in total

1.  Orbital Recurrence following Aggressive Laser Treatment for Recurrent Retinoblastoma.

Authors:  Bradley H Jacobsen; Jesse L Berry; Rima Jubran; Jonathan W Kim
Journal:  Ocul Oncol Pathol       Date:  2015-09-18

2.  Persistent Retinal Detachment in Retinoblastoma: The Challenges.

Authors:  Sophia El Hamichi; Dhariana Acon; Veronica Kon Graversen; Aaron S Gold; Audina M Berrocal; Timothy G Murray
Journal:  J Ophthalmol       Date:  2020-09-10       Impact factor: 1.909

3.  Proliferative Vitreoretinopathy in Treated Retinoblastoma.

Authors:  Cindy S Hwang; Pia R Mendoza; Jill R Wells; Hans E Grossniklaus; G Baker Hubbard
Journal:  Ophthalmol Retina       Date:  2017 Mar-Apr

4.  Outcomes of cataract surgery following radiation treatment for retinoblastoma.

Authors:  John F Payne; Amy K Hutchinson; G Baker Hubbard; Scott R Lambert
Journal:  J AAPOS       Date:  2009-10       Impact factor: 1.220

5.  Predictive factors of invasion in eyes with retinoblastoma enucleated after eye salvage treatments.

Authors:  Julia Balaguer; Matthew W Wilson; Catherine A Billups; John Mancini; Barrett G Haik; Ibrahim Qaddoumi; Joseph D Khoury; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

6.  Segmental Scleral Buckle Surgical Technique for Repair of a Rhegmatogenous Retinal Detachment in Retinoblastoma: A Case and Review of the Literature.

Authors:  Sydney P Wendt; Dianne A Barrett; Emmanuel Y Chang; Amy C Schefler
Journal:  Ocul Oncol Pathol       Date:  2020-12-22

7.  Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013.

Authors:  Francis L Munier
Journal:  Ophthalmic Genet       Date:  2014-10-16       Impact factor: 1.803

8.  Management of retinal detachment in retinoblastoma with globe conserving treatment.

Authors:  Ibrahim Elaraoud; Soon Ch'ng; David Karl; Dimitrios Kalogeropoulos; Randhir Chavan; Ash Sharma
Journal:  J Curr Ophthalmol       Date:  2018-09-22

9.  Pars plana vitrectomy under melphalan irrigation for recurrent retinal detachment in eyes treated for retinoblastoma: a case report.

Authors:  Christina Stathopoulos; Jessica Sergenti; Marie-Claire Gaillard; Francis L Munier; Alejandra Daruich
Journal:  BMC Ophthalmol       Date:  2020-01-28       Impact factor: 2.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.